Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.

@article{Kosmas1995AntichelateAA,
  title={Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.},
  author={Christos Kosmas and Anthony Maraveyas and Calvin Gooden and Derek Snook and Agamemnon A. Epenetos},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={1995},
  volume={36 5},
  pages={746-53}
}
UNLABELLED The development of stable chelating agents for metal isotopes (e.g., 90Y) such as CITC-DTPA, a benzyl-analog of DTPA, allowed us to evaluate the efficacy of 90Y-labeled HMFG1 MAb administered intraperitoneally in patients with ovarian cancer. Our previous studies of 90Y-HMFG1 antibody, however, showed that all patients developed anti-chelate antibody responses (to the macrocycle benzyl-DOTA), resulting in clinical side effects in a significant percentage of this group. METHODS We… CONTINUE READING